September 2010

 

OPHTHALMOLOGY NEWS

 

Biopharma company teams with Schepens Eye Research Institute


   

Schepens Eye Research Institute, an affiliate of Harvard Medical School, has teamed up with NeoStem Inc. (New York), to sponsor the research of Michael Young, Ph.D., and Kameran Lashkari, M.D. Dr. Young, director of the institute's Minda de Gunzburg Center for Ocular Regeneration, and Dr. Lashkari will be studying the development of novel therapies for age-related macular degeneration (AMD) and glaucoma, specifically examining the regenerative potential of NeoStem's VSEL Technology. Known as "stem cell play with a twist," VSEL utilizes the very small embryonic-like stem cells found in adult bone marrow. The stem cells have similar properties to embryonic stem cells and could achieve the same positive benefits without the ethical or moral dilemmas that come with it. Dr. Lashkari and Dr. Young's research will use animal models to assess VSEL's potential to combat AMD and glaucoma. "Our goal in this project is to gain a better understanding of the plasticity of stem cells from different compartments of the body, and the very small embryonic-like stem cells from NeoStem represent an exciting new source of cells with potential to repair the diseased central nervous system, including the retina," Dr. Young said in a statement.

Reported by EyeWorld News Services

Biopharma company teams with Schepens Eye Research Institute Biopharma company teams with Schepens Eye Research Institute
Ophthalmology News - EyeWorld Magazine
283 110
283 110
,
2016-07-08T15:40:10Z
True, 9